Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation
Open Access
- 1 January 2012
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 3, 20778
- https://doi.org/10.3389/fphar.2012.00006
Abstract
The human cardiac sodium channel (hNav1.5, encoded by the SCN5A gene) is critical for action potential generation and propagation in the heart. Drug-induced sodium channel inhibition decreases the rate of cardiomyocyte depolarization and consequently conduction velocity and can have serious implications for cardiac safety. Genetic mutations in hNav1.5 have also been linked to a number of cardiac diseases. Therefore, off-target hNav1.5 inhibition may be considered a risk marker for a drug candidate. Given the potential safety implications for patients and the costs of late stage drug development, detection, and mitigation of hNav1.5 liabilities early in drug discovery and development becomes important. In this review, we describe a pre-clinical strategy to identify hNav1.5 liabilities that incorporates in vitro, in vivo, and in silico techniques and the application of this information in the integrated risk assessment at different stages of drug discovery and development.This publication has 50 references indexed in Scilit:
- A Computational Model to Predict the Effects of Class I Anti-Arrhythmic Drugs on Ventricular RhythmsScience Translational Medicine, 2011
- On the relationship between block of the cardiac Na+channel and drug-induced prolongation of the QRS complexBritish Journal of Pharmacology, 2011
- The ‘overly-sensitive’ heart: sodium channel block and QRS interval prolongationBritish Journal of Pharmacology, 2011
- Lead Optimization Using Matched Molecular Pairs: Inclusion of Contextual Information for Enhanced Prediction of hERG Inhibition, Solubility, and LipophilicityJournal of Chemical Information and Modeling, 2010
- Activation of reverse Na+-Ca2+exchange by the Na+current augments the cardiac Ca2+transient: evidence from NCX knockout miceThe Journal of Physiology, 2010
- Drug‐ and non‐drug‐associated QT interval prolongationBritish Journal of Clinical Pharmacology, 2010
- Predicting drug‐induced slowing of conduction and pro‐arrhythmia: identifying the ‘bad’ sodium current blockersBritish Journal of Pharmacology, 2010
- Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path InitiativeAmerican Heart Journal, 2009
- Tricyclic Antidepressant PoisoningToxicological Reviews, 2005
- Assignment of the human heart tetrodotoxin-resistant voltage-gated Na+ channel α-subunit gene (SCN5A) to band 3p21Cytogenetic and Genome Research, 1995